Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590343 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
A Phase 2 study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00590343 is a Phase 2 study that has completed, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 23 participants.
The verdict
NCT00590343, a Phase 2 study, has completed, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to examine if PTK787/ZK222584 (vatalanib) will stabilize or decrease rising biochemical markers along with progressive disease or syndrome symptoms in patients with metastatic neuroendocrine tumors.
Interventions
- DRUG vatalanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-11 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590343
The ClinicalTrials.gov registry entry for NCT00590343 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center in New Orleans, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vatalanib is the first listed.
NCT00590343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590343 about?
NCT00590343 is a clinical study titled "Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors". The purpose of this study is to examine if PTK787/ZK222584 (vatalanib) will stabilize or decrease rising biochemical markers along with progressive disease or syndrome symptoms in patients with metastatic neuroendocrine tumors.
What is the current status of trial NCT00590343?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-11. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00590343?
The interventions under investigation include: vatalanib (DRUG).
Who is sponsoring clinical trial NCT00590343?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.